HUNTERASE - Drug for the Long-Term Treatment of Patients with Hunter Syndrome
HUNTERASE® is indicated for the long-term treatment of patients with Hunter syndrome (mucopolysaccharidosis type II, MPS II)
-
Most popular related searches
HUNTERASE® (INN: idursulfase beta) is drug for...
HUNTERASE® (INN: idursulfase beta) is drug for the long-term treatment of patients with Hunter syndrome (mucopolysaccharidosis type II, MPS II).
Idursulfatase beta is a purified form of iduronate-2-sulfatase lysosomalenzyme: recombinant human iduronate-2-sulfatase (rhI2S)
The efficacy and safety of Hunterase were demonstrated in two clinical studies with a duration of 24–52 weeks including male patients with Hunter syndrome aged 38 months to 35 years (see the Instruction for Medical Use)
DOSAGE FORM
DOSAGE FORM
Concentrate for solution for injection 2 mg/ml
SHELF LIFE
2 years at 2–8 °C in a dark place
INDICATIONS
HUNTERASE® is indicated for the long-term treatment of patients with Hunter syndrome (mucopolysaccharidosis type II, MPS II)*
MARKETING AUTHORIZATION OWNER
NANOLEK LLC, MA No. LP-004673 (??-004673), 2018
Consult a physician before use and read the Instruction for Medical Use. The information provided on this website is not a substitution for consultations with a physician and shall not be considered as such.
Dosage form
Dosage form
Concentrate for solution for injection 2 mg/ml
INN
idursulfase beta
Customer reviews
No reviews were found for HUNTERASE - Drug for the Long-Term Treatment of Patients with Hunter Syndrome. Be the first to review!